help button home button Endocrine Society Endocrinology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

Endocrinology, doi:10.1210/en.2005-0644
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
147/3/1377    most recent
Author Manuscript (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Fujita, Y.
Right arrow Articles by Tamaki, T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Fujita, Y.
Right arrow Articles by Tamaki, T.
Endocrinology Vol. 147, No. 3 1377-1385
Copyright © 2006 by The Endocrine Society

Transactivation of Fetal Liver Kinase-1/Kinase-Insert Domain-Containing Receptor by Lysophosphatidylcholine Induces Vascular Endothelial Cell Proliferation

Yoshiko Fujita, Masanori Yoshizumi, Yuki Izawa, Nermin Ali, Hideki Ohnishi, Yasuhisa Kanematsu, Keisuke Ishizawa, Koichiro Tsuchiya and Toshiaki Tamaki

Department of Pharmacology (Y.F., M.Y., Y.I., N.A., H.O., Y.K., K.I., T.T.), Graduate School of Medical Sciences, and Department of Clinical Pharmacology (K.T.), Graduate School of Pharmaceutical Sciences, The University of Tokushima Graduate School, Tokushima 770-8503, Japan

Address all correspondence and requests for reprints to: Yoshiko Fujita, Department of Pharmacology, The University of Tokushima Graduate School of Medical Sciences, 3-18-15 Kuramoto, Tokushima 770-8503, Japan. E-mail: fujita56{at}ri.ncvc.go.jp.

Lysophosphatidylcholine (LPC), a major lipid component of oxidized low-density lipoprotein, is a bioactive lipid molecule involved in numerous biological processes including the progression of atherosclerosis. Recently orphan G protein-coupled receptors were identified as high-affinity receptors for LPC. Although several G protein-coupled receptor ligands transactivate receptor tyrosine kinases, LPC-stimulated transactivation of receptor tyrosine kinase has not yet been reported. Here we observed for the first time that LPC treatment of human umbilical vein endothelial cells (HUVECs) induces tyrosyl phosphorylation of vascular endothelial growth factor receptor 2 [fetal liver kinase-1/kinase-insert domain-containing receptor, Flk-1/KDR)]. Flk-1/KDR transactivation by LPC was inhibited by vascular endothelial growth factor receptor tyrosine kinase inhibitors, SU1498 and 4-[(4'-chrolo-2'-fluoro) phenylamino]6,7-dimethoxyquinazoline (VTKi) in immunoprecipitation. Furthermore, we examined the effects of the Src family kinases inhibitors, herbimycin A and 4-amino-5-(4-chlorophenyl)-7-(t-butyl) pyrazolo[3,4-d] pyrimidine (PP2), on LPC-induced Flk-1/KDR transactivation. Results from Western blots, c-Src is involved in LPC-induced Flk-1/KDR transactivation because herbimycin A and PP2 inhibited this transactivation. Kinase-inactive (KI) Src transfection also inhibited LPC-induced Flk-1/KDR transactivation. In addition, results from Western blots, ERK1/2 and Akt, which are downstream effectors of Flk-1/KDR, were also activated by LPC, and this was inhibited by SU1498, VTKi, herbimycin A, PP2, and KI Src transfection in HUVECs. LPC-induced stimulation of HUVEC proliferation was shown to be secondary to transactivation because it was suppressed by SU1498, VTKi, herbimycin A, PP2, and KI Src transfection in dimethylthiazoldiphenyltetra-zoliumbromide assay. These findings suggest that LPC-induced Flk-1/KDR transactivation via c-Src may have important implications for the progression of atherosclerosis.




This article has been cited by other articles:


Home page
FASEB J.Home page
Y. Greenberg, M. King, W. B. Kiosses, K. Ewalt, X. Yang, P. Schimmel, J. S. Reader, and E. Tzima
The novel fragment of tyrosyl tRNA synthetase, mini-TyrRS, is secreted to induce an angiogenic response in endothelial cells
FASEB J, May 1, 2008; 22(5): 1597 - 1605.
[Abstract] [Full Text] [PDF]


Home page
Mol. Biol. CellHome page
M. L. Petreaca, M. Yao, Y. Liu, K. DeFea, and M. Martins-Green
Transactivation of Vascular Endothelial Growth Factor Receptor-2 by Interleukin-8 (IL-8/CXCL8) Is Required for IL-8/CXCL8-induced Endothelial Permeability
Mol. Biol. Cell, December 1, 2007; 18(12): 5014 - 5023.
[Abstract] [Full Text] [PDF]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
A. Zimman, K. P. Mouillesseaux, T. Le, N. M. Gharavi, A. Ryvkin, T. G. Graeber, T. T. Chen, A. D. Watson, and J. A. Berliner
Vascular Endothelial Growth Factor Receptor 2 Plays a Role in the Activation of Aortic Endothelial Cells by Oxidized Phospholipids
Arterioscler. Thromb. Vasc. Biol., February 1, 2007; 27(2): 332 - 338.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
D.-Y. Xuan, X. Li, Z.-H. Deng, H.-L. Zhang, P.-x. Feng, X.-Y. Duan, and Y. Jin
Identification and Characterization of a Novel Gene, Mcpr1, and Its Possible Function in the Proliferation of Embryonic Palatal Mesenchymal Cells
J. Biol. Chem., November 10, 2006; 281(45): 33997 - 34008.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 2006 by The Endocrine Society